Zacks Investment Research upgraded shares of Biohaven Pharmaceutical (NYSE:BHVN) from a hold rating to a buy rating in a report published on Monday morning. The firm currently has $25.00 price objective on the stock.

According to Zacks, “Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company’s pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. “

A number of other research firms have also weighed in on BHVN. BidaskClub upgraded shares of Biohaven Pharmaceutical from a buy rating to a strong-buy rating in a research report on Thursday, September 7th. Needham & Company LLC reiterated a buy rating and issued a $43.00 price target (up from $30.00) on shares of Biohaven Pharmaceutical in a research report on Wednesday, September 13th. Piper Jaffray Companies reiterated a buy rating and issued a $54.00 price target on shares of Biohaven Pharmaceutical in a research report on Tuesday, September 12th. Morgan Stanley upped their price target on shares of Biohaven Pharmaceutical from $28.00 to $47.00 and gave the stock an overweight rating in a research report on Monday, September 25th. Finally, William Blair reissued an outperform rating on shares of Biohaven Pharmaceutical in a report on Tuesday, October 3rd. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $38.17.

Biohaven Pharmaceutical (NYSE BHVN) traded up $0.35 on Monday, hitting $20.79. 391,400 shares of the company’s stock were exchanged, compared to its average volume of 218,611. Biohaven Pharmaceutical has a fifty-two week low of $17.00 and a fifty-two week high of $39.51.

In other news, insider John Tilton sold 30,000 shares of the business’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $29.25, for a total value of $877,500.00. Following the transaction, the insider now owns 30,000 shares of the company’s stock, valued at $877,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Vlad Coric sold 150,000 shares of the business’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $29.41, for a total transaction of $4,411,500.00. The disclosure for this sale can be found here. Insiders sold 439,131 shares of company stock worth $12,011,701 in the last three months.

Several hedge funds have recently added to or reduced their stakes in BHVN. Deschutes Portfolio Strategy LLC purchased a new position in shares of Biohaven Pharmaceutical in the third quarter worth $374,000. Strs Ohio purchased a new stake in Biohaven Pharmaceutical during the third quarter valued at $680,000. Nationwide Fund Advisors purchased a new stake in Biohaven Pharmaceutical during the third quarter valued at $214,000. Emerald Advisers Inc. PA purchased a new stake in Biohaven Pharmaceutical during the third quarter valued at $9,096,000. Finally, Emerald Mutual Fund Advisers Trust purchased a new stake in Biohaven Pharmaceutical during the third quarter valued at $7,483,000. 47.76% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Biohaven Pharmaceutical (BHVN) Upgraded to Buy by Zacks Investment Research” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/biohaven-pharmaceutical-bhvn-upgraded-to-buy-by-zacks-investment-research/1752078.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Get a free copy of the Zacks research report on Biohaven Pharmaceutical (BHVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.